Literature DB >> 28017788

Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non-Small Cell Lung Cancer.

Yuko Usui1, Hibiki Udagawa2, Shingo Matsumoto2, Kenjiro Imai3, Ken Ohashi3, Masayuki Ishibashi2, Keisuke Kirita2, Shigeki Umemura2, Kiyotaka Yoh2, Seiji Niho2, Keiichiro Osame3, Koichi Goto2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28017788     DOI： 10.1016/j.jtho.2016.12.015

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  29 in total

1.  Diabetes mellitus secondary to treatment with immune checkpoint inhibitors.

Authors:  V Venetsanaki; A Boutis; A Chrisoulidou; P Papakotoulas
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

2.  A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma.

Authors:  C Sakaguchi; K Ashida; S Yano; K Ohe; N Wada; N Hasuzawa; Y Matsuda; S Sakamoto; R Sakamoto; H Uchi; M Furue; M Nomura; Y Ogawa
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

Review 3.  Anti-programmed Cell Death Protein-1 Therapy in Intrahepatic Cholangiocarcinoma Induced Type 1 Diabetes: A Case Report and Literature Review.

Authors:  Zhi-Kai Zheng; Jiong-Liang Wang; Wen-Xuan Li; Tian-Qing Wu; Min-Shan Chen; Zhong-Guo Zhou
Journal:  Front Public Health       Date:  2022-06-16

4.  New onset diabetes after nivolumab treatment.

Authors:  Ricardo Capitao; Carlos Bello; Ricardo Fonseca; Catarina Saraiva
Journal:  BMJ Case Rep       Date:  2018-01-29

Review 5.  Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?

Authors:  Angelos Kyriacou; Eka Melson; Wentin Chen; Punith Kempegowda
Journal:  Clin Med (Lond)       Date:  2020-07       Impact factor: 2.659

Review 6.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Authors:  Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 7.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors:  Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal:  Clin Diabetes Endocrinol       Date:  2019-01-22

8.  Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies.

Authors:  Jingli Lu; Jing Yang; Yan Liang; Haiyang Meng; Junjie Zhao; Xiaojian Zhang
Journal:  Front Pharmacol       Date:  2019-12-06       Impact factor: 5.810

Review 9.  The side effects of immune checkpoint inhibitor therapy on the endocrine system.

Authors:  Itivrita Goyal; Manu Raj Pandey; Rajeev Sharma; Ajay Chaudhuri; Paresh Dandona
Journal:  Indian J Med Res       Date:  2021-04       Impact factor: 5.274

10.  Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy.

Authors:  Megu Yamaguchi Baden; Akihisa Imagawa; Norio Abiru; Takuya Awata; Hiroshi Ikegami; Yasuko Uchigata; Yoichi Oikawa; Haruhiko Osawa; Hiroshi Kajio; Eiji Kawasaki; Yumiko Kawabata; Junji Kozawa; Akira Shimada; Kazuma Takahashi; Shoichiro Tanaka; Daisuke Chujo; Tomoyasu Fukui; Junnosuke Miura; Kazuki Yasuda; Hisafumi Yasuda; Tetsuro Kobayashi; Toshiaki Hanafusa
Journal:  Diabetol Int       Date:  2018-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.